| The systematic production of cells for cell therapies DC Kirouac, PW Zandstra Cell stem cell 3 (4), 369-381, 2008 | 352 | 2008 |
| Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling E Csaszar, DC Kirouac, M Yu, WJ Wang, W Qiao, MP Cooke, AE Boitano, ... Cell stem cell 10 (2), 218-229, 2012 | 296 | 2012 |
| Dynamic interaction networks in a hierarchically organized tissue DC Kirouac, C Ito, E Csaszar, A Roch, M Yu, EA Sykes, GD Bader, ... Molecular systems biology 6 (1), 417, 2010 | 159 | 2010 |
| Cell–cell interaction networks regulate blood stem and progenitor cell fate DC Kirouac, GJ Madlambayan, M Yu, EA Sykes, C Ito, PW Zandstra Molecular systems biology 5 (1), 293, 2009 | 140 | 2009 |
| A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types MC Wagle, D Kirouac, C Klijn, B Liu, S Mahajan, M Junttila, J Moffat, ... NPJ precision oncology 2 (1), 7, 2018 | 137 | 2018 |
| Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors DC Kirouac, JY Du, J Lahdenranta, R Overland, D Yarar, V Paragas, ... Science signaling 6 (288), ra68-ra68, 2013 | 124 | 2013 |
| Dynamic changes in cellular and microenvironmental composition can be controlled to elicit in vitro human hematopoietic stem cell expansion GJ Madlambayan, I Rogers, DC Kirouac, N Yamanaka, F Mazurier, ... Experimental hematology 33 (10), 1229-1239, 2005 | 96 | 2005 |
| Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors M Merchant, J Moffat, G Schaefer, J Chan, X Wang, C Orr, J Cheng, ... PloS one 12 (10), e0185862, 2017 | 93 | 2017 |
| Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks DC Kirouac, J Saez-Rodriguez, J Swantek, JM Burke, DA Lauffenburger, ... BMC systems biology 6, 1-17, 2012 | 87 | 2012 |
| A six‐stage workflow for robust application of systems pharmacology K Gadkar, DC Kirouac, DE Mager, PH van der Graaf, S Ramanujan CPT: pharmacometrics & systems pharmacology 5 (5), 235-249, 2016 | 83 | 2016 |
| Clinically relevant expansion of hematopoietic stem cells with conserved function in a single-use, closed-system bioprocess GJ Madlambayan, I Rogers, KA Purpura, C Ito, M Yu, D Kirouac, ... Biology of Blood and Marrow Transplantation 12 (10), 1020-1030, 2006 | 63 | 2006 |
| Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model DC Kirouac, G Schaefer, J Chan, M Merchant, C Orr, SMA Huang, J Moffat, ... NPJ systems biology and applications 3 (1), 14, 2017 | 62 | 2017 |
| HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B DC Kirouac, J Du, J Lahdenranta, MD Onsum, UB Nielsen, B Schoeberl, ... PLoS computational biology 12 (4), e1004827, 2016 | 48 | 2016 |
| Understanding cellular networks to improve hematopoietic stem cell expansion cultures DC Kirouac, PW Zandstra Current opinion in biotechnology 17 (5), 538-547, 2006 | 41 | 2006 |
| Reproducibility of quantitative systems pharmacology models: current challenges and future opportunities DC Kirouac, B Cicali, S Schmidt CPT: pharmacometrics & systems pharmacology 8 (4), 205-210, 2019 | 37 | 2019 |
| Quantitative systems pharmacology: a promising approach for translational pharmacology K Gadkar, D Kirouac, N Parrott, S Ramanujan Drug Discovery Today: Technologies 21, 57-65, 2016 | 37 | 2016 |
| Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology DC Kirouac, MD Onsum CPT: pharmacometrics & systems pharmacology 2 (9), 1-7, 2013 | 35 | 2013 |
| Deconvolution of clinical variance in CAR-T cell pharmacology and response DC Kirouac, C Zmurchok, A Deyati, J Sicherman, C Bond, PW Zandstra Nature Biotechnology 41 (11), 1606-1617, 2023 | 25 | 2023 |
| The AC133+CD38−, but not the rhodamine-low, phenotype tracks LTC-IC and SRC function in human cord blood ex vivo expansion cultures CY Ito, DC Kirouac, GJ Madlambayan, M Yu, I Rogers, PW Zandstra Blood, The Journal of the American Society of Hematology 115 (2), 257-260, 2010 | 24 | 2010 |
| How do we “validate” a QSP model? DC Kirouac CPT: Pharmacometrics & Systems Pharmacology 7 (9), 547, 2018 | 20 | 2018 |
Edward A. SykesPhD, IBBME, University of Toronto & Queen's School of MedicineVerified email at queensu.ca
